Get started
Nykode Therapeutics ASANykode Therapeutics ASANykode Therapeutics ASA

Nykode Therapeutics ASA

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityForecastsSeasonals

Documents


Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.
2026
Investor presentation
Jul 22, 2026
AI-driven APC-targeting vaccines show strong, durable immune responses and clinical promise.
Earnings, Q1 FY2026
May 27, 2026
Abi-suva phase II trial underway with strong interim data; cash runway extends into 2028.
Company presentation
May 27, 2026
APC-targeted immunotherapies and AI-driven platforms drive strong clinical and pipeline progress.
25th BioPharma Drug Discovery presentation
Apr 29, 2026
AI-powered immunotherapy design enables rapid, personalized cancer vaccine development.
Development of APC-targeted antigen-apecific immune tolerance therapies for autoimmune diseases presentation
Mar 25, 2026
APC-targeted immunotherapies show strong preclinical efficacy and rapid AI-driven development.
VB10.NEO presentation
Mar 24, 2026
Individualized neoantigen vaccines show robust, durable immunity and streamlined production.
ICHNO 2026 presentation
Mar 20, 2026
Abi-suva plus pembrolizumab achieved strong immune responses and 38.5% ORR in HPV16+ OPC.
DNB Carnegie Nordic Healthcare Conference presentation
Mar 10, 2026
Advancing APC-targeted immunotherapies with strong clinical data and a solid financial runway.
9th ASIT 2026 presentation
Mar 5, 2026
APC-targeted immunotherapies deliver durable, antigen-specific efficacy and rapid clinical progress.
Investor presentation
Feb 25, 2026
Strong clinical progress in oncology and immune tolerance platforms, with robust financial runway.
Company presentation
Jan 9, 2026
Advancing APC-targeted immunotherapies with strong clinical data and robust financial runway.
2025
Earnings, Q4 FY2025
Annual
Feb 25, 2026
Clinical advances and cost discipline position the pipeline for key data and milestones in 2026-2027.
DNB Carnegie Nordic Healthcare Conference presentation
Nov 25, 2025
Advancing oncology and autoimmune therapies with strong data, innovative platforms, and solid funding.
Earnings, Q3 FY2025
Nov 24, 2025
Advanced clinical pipeline, strengthened IP, and extended cash runway with reduced losses.
HCW Annual Global Investment Conference presentation
Sep 10, 2025
Strong clinical pipeline in oncology and autoimmune diseases, with robust financial runway.
Earnings, Q2 FY2025
Aug 27, 2025
Strategic focus shifts to VB10.16, with strong data, reduced costs, and a robust cash runway.
Earnings, Q1 FY2025
May 28, 2025
Streamlined operations, strong cash, and promising clinical data set stage for strategic updates.
ASIT 2025 presentation
Feb 27, 2025
AI-powered APC-targeted vaccines show durable efficacy in cancer and autoimmune models.
2024
Earnings, Q4 FY2024
Annual
Feb 26, 2025
Strategic refocus and strong cash reserves position Nykode for pipeline advancement and partnerships.
Personalized cancer vaccine summit presentation
Dec 4, 2024
Earnings, Q3 FY2024
Nov 27, 2024
Status Update
Nov 8, 2024
PEGS EUROPE 2024 presentation
Nov 7, 2024
Earnings, Q2 FY2024
Aug 21, 2024